This bill amends R.S. 22:1053(A)(2) to clarify the coverage requirements for step therapy or fail first protocols in Louisiana. Specifically, it adds the term "biosimilar" to the list of products that can be substituted under these protocols, alongside AB-rated generic equivalents and interchangeable biological products as designated by the federal Food and Drug Administration.

The amendment ensures that the substitution of biosimilar products is explicitly permitted, thereby expanding the options available to patients and healthcare providers when it comes to medication management. This change aims to enhance access to effective treatments while maintaining compliance with federal regulations regarding biological products.

Statutes affected:
HB403 Original: 22:1053(A)(2)
HB403 Engrossed: 22:1053(A)(2)
HB403 Enrolled: 22:1053(A)(2)
HB403 Act 125: 22:1053(A)(2)